Skip to main content
OpenTrials
Completed

NCT Number: NCT04559984

JUVÉDERM VOLUX® for Chin Retrusion in China

The objective of this study is to evaluate the safety and effectiveness of JUVÉDERM VOLUX® to correct moderate to severe chin retrusion in Chinese adults.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Beijing Hospital /ID# 224440, Beijing, Beijing Municipality, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participant must be at least 18 years of age at the time of signing the ICF
  • Male and female
  • Participants of Chinese descent
  • Participants seeking improvement of chin retrusion
  • Chin retrusion (G-Sn-Pog angle of < 172.5°) based on calculations of facial angle derived from digital images obtained using Canfield imaging equipment and software
  • Has moderate to severe chin retrusion on the CACRS as determined by EI 2D image evaluation
  • Has a reasonable goal for aesthetic improvement in chin retrusion and is able to achieve a 1-point improvement in CACRS score with study intervention in the judgment of TI
  • Capable of giving signed informed consent as described in Appendix 10.1.3, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol
  • Written informed consent from the participant has been obtained prior to any study-related procedures
  • Written documentation has been obtained in accordance with the relevant country and local privacy requirements, where applicable

Exclusion criteria

  • History of tendency to develop hypertrophic scarring
  • History of anaphylaxis or allergy to lidocaine (or any amide-based anesthetics), HA products, or streptococcal protein
  • Active autoimmune disease
  • Current cutaneous inflammatory or infectious processes (eg, acne, herpes), abscess, an unhealed wound, or a cancerous or precancerous lesion in the chin area (participants with a history of recurrent oral herpes are eligible if prophylactic antiviral/herpes medication is administered for 2 days before study intervention)
  • Impaired cardiac conduction, impaired hepatic function, or impaired renal function according to the judgment of the TI based on medical history, laboratory testing results, and other clinical signs and symptoms
  • Prior chin or jaw surgery, including cartilage grafts or implantation of any biomaterials
  • Permanent dermal filler injected below the subnasale
  • Semi-permanent dermal filler or fat injected below the subnasale within 36 months before enrollment
  • Temporary dermal filler injected below the subnasale within 12 months before enrollment
  • Orthodontics procedures within 12 months before enrollment
  • Botulinum toxin treatment in the chin area within 6 months before enrollment
  • Mesotherapy or cosmetic facial procedures (eg, face-lift, brow lift, facial reconstructive surgery, laser, photomodulation, intense pulsed light, radio frequency, dermabrasion, moderate or greater depth chemical peel, or other ablative procedures) below the subnasale within 6 months before enrollment
  • Current enrollment in an investigational drug or device study or participation in such a study within 30 days before enrollment
  • Abnormal and clinically significant results according to the TI or designee, on hematology, clinical chemistry, or urinalysis
  • Females who are pregnant, nursing, or planning a pregnancy during the study
  • Tattoos, piercings or scars that would interfere with study visual assessments and 3D measurements of chin area in the judgment of TI
  • Trauma to the chin or has residual deficiencies, congenital deformities, or scarring which would impact the trial data evaluation in the judgment of TI
  • Menstruation at the time of study intervention (study intervention may be delayed as necessary to accommodate menstrual period cessation)
  • The participant has a condition or is in a situation which, in the TI's opinion, may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant's participation in the study

Treatment and study plan

JUVÉDERM VOLUX®

Device

JUVÉDERM VOLUX® injectable gel

Primary outcomes

  1. Change from baseline in glabella-subnasale-pogonion (G-Sn-Pog) angle at Week 24

    Time frame: Change from Baseline to Week 24

    The G-Sn-Pog angle is the angle formed by the point on the glabella, subnasale, and pogonion.

Secondary outcomes

  1. China (Allergan) Chin Retrusion Scale (CACRS) responder status based on the Evaluating Investigator's (EI) assessment of 2D images at Week 24

    Time frame: Week 24

    The CACRS is a validated 5-point ordinal scale developed by Allergan to grade the severity of chin retrusion. The scale ranges from 0=none to 4=severe.

  2. Overall scores of Satisfaction with Chin module of the FACE-Q questionnaire at Week 24

    Time frame: Week 24

    The subject will assess satisfaction using the 10 items on the Satisfaction with Chin FACE-Q.

  3. Responder status for participant and EI assessments of global aesthetic improvement in the chin and jaw area using the Global Aesthetic Improvement Scale (GAIS) at Week 24

    Time frame: Week 24

    The GAIS is a 5-point scale where: 2=much improved, 1=improved, 0=no change, -1=worse and -2=much worse.

  4. Number of patients experiencing one or more treatment emergent adverse events (TEAEs)

    Time frame: Up to week 52

    The number of patients who experienced one or more TEAEs

Sponsors and collaborators

Lead sponsor

Allergan

Industry

Registry information

Official study title

A Randomized, Multicenter, "No-Treatment" Control Study to Evaluate the Safety and Effectiveness of JUVÉDERM VOLUX® Injectable Gel for the Enhancement of the Chin to Correct Moderate to Severe Retrusion in Chinese Adults

Important dates

Study start
2020
Primary completion
2022
Study completion
2022
First posted
Sep 23, 2020
Registry last updated
Aug 21, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.